Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants

Soo Jin Park, Jong Kuk Kim, Hyun Hwi Kim, Byeol A. Yoon, Dong Yoon Ji, Chang Wan Lee, Ho Jin Kim, Kyoung Heon Kim, Ha Young Shin, Sung Jean Park, Do Yup Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Guillain–Barré syndrome (GBS) is an acute fatal progressive disease caused by autoimmune mechanism mainly affecting peripheral nervous system. Although the syndrome is clinically sub-classified into several variants, specific biomarker and exact pathomechanism of each subtypes are not well elucidated yet. In current study, integrative metabolomic and lipidomic profiles were acquisitioned from cerebrospinal fluid samples of 86 GBS from three variants and 20 disease controls. And the data were systematically compared to our previous result on inflammatory demyelination disorders of central nervous system (IDDs) and healthy controls. Primary metabolite profiles revealed unique metabolic traits in which 9 and 7 compounds were specifically changed in GBS and IDD, respectively. Next, the biomarker panel with 10 primary metabolites showed a fairly good discrimination power among 3 GBS subtypes, healthy controls, and disease controls (AUCs ranged 0.849–0.999). The robustness of the biomarker panel was vigorously validated by multi-step statistical evaluation. Subsequent lipidomics revealed GBS variant-specific alteration where the significant elevations of lyso-phosphatidylcholines and sphingomyelins were unique to AIDP (acute inflammatory demyelinating polyneuropathy) and AMAN (acute motor axonal neuropathy), respectively. And metabolome-wide multivariate correlation analysis identified potential clinical association between GBS disability scale (Hughes score) and CSF lipids (monoacylglycerols, and sphingomyelins). Finally, Bayesian network analysis of covarianced structures of primary metabolites and lipids proposed metabolic hub and potential biochemical linkage associated with the pathology.

Original languageEnglish
Article number1077
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Metabolomics
Guillain-Barre Syndrome
Sphingomyelins
Biomarkers
Monoglycerides
Lipids
Bayes Theorem
Metabolome
Central Nervous System Diseases
Peripheral Nervous System
Demyelinating Diseases
Phosphatidylcholines
Autoimmune Diseases
Area Under Curve
Cerebrospinal Fluid
Multivariate Analysis
Pathology

ASJC Scopus subject areas

  • General

Cite this

Park, S. J., Kim, J. K., Kim, H. H., Yoon, B. A., Ji, D. Y., Lee, C. W., ... Lee, D. Y. (2019). Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. Scientific Reports, 9(1), [1077]. https://doi.org/10.1038/s41598-018-37572-w

Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. / Park, Soo Jin; Kim, Jong Kuk; Kim, Hyun Hwi; Yoon, Byeol A.; Ji, Dong Yoon; Lee, Chang Wan; Kim, Ho Jin; Kim, Kyoung Heon; Shin, Ha Young; Park, Sung Jean; Lee, Do Yup.

In: Scientific Reports, Vol. 9, No. 1, 1077, 01.12.2019.

Research output: Contribution to journalArticle

Park, SJ, Kim, JK, Kim, HH, Yoon, BA, Ji, DY, Lee, CW, Kim, HJ, Kim, KH, Shin, HY, Park, SJ & Lee, DY 2019, 'Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants', Scientific Reports, vol. 9, no. 1, 1077. https://doi.org/10.1038/s41598-018-37572-w
Park, Soo Jin ; Kim, Jong Kuk ; Kim, Hyun Hwi ; Yoon, Byeol A. ; Ji, Dong Yoon ; Lee, Chang Wan ; Kim, Ho Jin ; Kim, Kyoung Heon ; Shin, Ha Young ; Park, Sung Jean ; Lee, Do Yup. / Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{db653a15f3494c2785ac6f736540e01e,
title = "Integrative metabolomics reveals unique metabolic traits in Guillain-Barr{\'e} Syndrome and its variants",
abstract = "Guillain–Barr{\'e} syndrome (GBS) is an acute fatal progressive disease caused by autoimmune mechanism mainly affecting peripheral nervous system. Although the syndrome is clinically sub-classified into several variants, specific biomarker and exact pathomechanism of each subtypes are not well elucidated yet. In current study, integrative metabolomic and lipidomic profiles were acquisitioned from cerebrospinal fluid samples of 86 GBS from three variants and 20 disease controls. And the data were systematically compared to our previous result on inflammatory demyelination disorders of central nervous system (IDDs) and healthy controls. Primary metabolite profiles revealed unique metabolic traits in which 9 and 7 compounds were specifically changed in GBS and IDD, respectively. Next, the biomarker panel with 10 primary metabolites showed a fairly good discrimination power among 3 GBS subtypes, healthy controls, and disease controls (AUCs ranged 0.849–0.999). The robustness of the biomarker panel was vigorously validated by multi-step statistical evaluation. Subsequent lipidomics revealed GBS variant-specific alteration where the significant elevations of lyso-phosphatidylcholines and sphingomyelins were unique to AIDP (acute inflammatory demyelinating polyneuropathy) and AMAN (acute motor axonal neuropathy), respectively. And metabolome-wide multivariate correlation analysis identified potential clinical association between GBS disability scale (Hughes score) and CSF lipids (monoacylglycerols, and sphingomyelins). Finally, Bayesian network analysis of covarianced structures of primary metabolites and lipids proposed metabolic hub and potential biochemical linkage associated with the pathology.",
author = "Park, {Soo Jin} and Kim, {Jong Kuk} and Kim, {Hyun Hwi} and Yoon, {Byeol A.} and Ji, {Dong Yoon} and Lee, {Chang Wan} and Kim, {Ho Jin} and Kim, {Kyoung Heon} and Shin, {Ha Young} and Park, {Sung Jean} and Lee, {Do Yup}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-018-37572-w",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants

AU - Park, Soo Jin

AU - Kim, Jong Kuk

AU - Kim, Hyun Hwi

AU - Yoon, Byeol A.

AU - Ji, Dong Yoon

AU - Lee, Chang Wan

AU - Kim, Ho Jin

AU - Kim, Kyoung Heon

AU - Shin, Ha Young

AU - Park, Sung Jean

AU - Lee, Do Yup

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Guillain–Barré syndrome (GBS) is an acute fatal progressive disease caused by autoimmune mechanism mainly affecting peripheral nervous system. Although the syndrome is clinically sub-classified into several variants, specific biomarker and exact pathomechanism of each subtypes are not well elucidated yet. In current study, integrative metabolomic and lipidomic profiles were acquisitioned from cerebrospinal fluid samples of 86 GBS from three variants and 20 disease controls. And the data were systematically compared to our previous result on inflammatory demyelination disorders of central nervous system (IDDs) and healthy controls. Primary metabolite profiles revealed unique metabolic traits in which 9 and 7 compounds were specifically changed in GBS and IDD, respectively. Next, the biomarker panel with 10 primary metabolites showed a fairly good discrimination power among 3 GBS subtypes, healthy controls, and disease controls (AUCs ranged 0.849–0.999). The robustness of the biomarker panel was vigorously validated by multi-step statistical evaluation. Subsequent lipidomics revealed GBS variant-specific alteration where the significant elevations of lyso-phosphatidylcholines and sphingomyelins were unique to AIDP (acute inflammatory demyelinating polyneuropathy) and AMAN (acute motor axonal neuropathy), respectively. And metabolome-wide multivariate correlation analysis identified potential clinical association between GBS disability scale (Hughes score) and CSF lipids (monoacylglycerols, and sphingomyelins). Finally, Bayesian network analysis of covarianced structures of primary metabolites and lipids proposed metabolic hub and potential biochemical linkage associated with the pathology.

AB - Guillain–Barré syndrome (GBS) is an acute fatal progressive disease caused by autoimmune mechanism mainly affecting peripheral nervous system. Although the syndrome is clinically sub-classified into several variants, specific biomarker and exact pathomechanism of each subtypes are not well elucidated yet. In current study, integrative metabolomic and lipidomic profiles were acquisitioned from cerebrospinal fluid samples of 86 GBS from three variants and 20 disease controls. And the data were systematically compared to our previous result on inflammatory demyelination disorders of central nervous system (IDDs) and healthy controls. Primary metabolite profiles revealed unique metabolic traits in which 9 and 7 compounds were specifically changed in GBS and IDD, respectively. Next, the biomarker panel with 10 primary metabolites showed a fairly good discrimination power among 3 GBS subtypes, healthy controls, and disease controls (AUCs ranged 0.849–0.999). The robustness of the biomarker panel was vigorously validated by multi-step statistical evaluation. Subsequent lipidomics revealed GBS variant-specific alteration where the significant elevations of lyso-phosphatidylcholines and sphingomyelins were unique to AIDP (acute inflammatory demyelinating polyneuropathy) and AMAN (acute motor axonal neuropathy), respectively. And metabolome-wide multivariate correlation analysis identified potential clinical association between GBS disability scale (Hughes score) and CSF lipids (monoacylglycerols, and sphingomyelins). Finally, Bayesian network analysis of covarianced structures of primary metabolites and lipids proposed metabolic hub and potential biochemical linkage associated with the pathology.

UR - http://www.scopus.com/inward/record.url?scp=85060937932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060937932&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-37572-w

DO - 10.1038/s41598-018-37572-w

M3 - Article

C2 - 30705347

AN - SCOPUS:85060937932

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1077

ER -